Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036361 · ClinicalTrials.gov registry record · Phase 3
Broad Effectiveness: Study With Aripiprazole
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
NCT00036361: Completed Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00036361 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 444 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036361, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
What the finished NCT00036361 record still lists
NCT00036361 is an interventional study that assigns participants to a tested intervention. The registered 444 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00036361 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036361 about?
NCT00036361 is a clinical study titled "Broad Effectiveness: Study With Aripiprazole". The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
What is the current status of trial NCT00036361?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2002-07. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00036361?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00036361?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00036361's enrollment target sits among peer trials
444 864th of 2000 higher than 1,135 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia